Skip to main content

Table 2 Univariate Analysis of Survival

From: Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter Pyloriinfection

UNIVARIATE ANALYSIS OF SURVIVAL
Variable MST 1-year survival % P-value
Age Category ≤ 60 16.50 53.00% 0.591
  >60 15.75 47.86%  
Gender Male 15.75 50.34% 0.515
  Female 16.50 49.3%  
  60-70 11.75 30.30%  
Karnofsky PS 80 16.75 52.40% <0.001
  90-100 19.25 63.20%  
  1 14.50 36.40% 0.092
Histological Grade 2 17.25 54.30%  
  3 14.25 44.87%  
Lymph node metastasis No 13.50 28.89% 0.051
  Yes 16.75 56.65%  
Liver metastasis No 19.25 63.39% <0.001
  Yes 12.75 37.74%  
Lung metastasis No 16.25 52.24% 0.185
  Yes 12.75 35.29%  
Ovarian metastasis No 16.00 51.27% 0.579
  Yes 17.00 47.62%  
Bone metastasis No 16.25 51.18% 0.282
  Yes 12.25 42.86%  
Peritoneal dissemination No 16.75 54.90% 0.319
  Yes 15.00 43.70%  
Albumin Normal 18.00 57.66% 0.002
  Low 12.75 38.30%  
CRP Normal 18.00 56.06% <0.001
  High 12.75 43.02%  
HP No 15.50 48.59% 0.35
  Yes 17.25 52.63%  
CEA ≤ 5 15.00 45.54% 0.143
  > 5 17.00 52.83%  
CA 19-9 ≤ 30 18.25 58.14% 0.019
  > 30 14.50 46.21%  
CA 72-4 ≤ 7 21.75 65.00% 0.002
  > 7 14.75 47.46%  
  Low 22.50 73.86%  
DNA Index Medium 12.75 35.20% <0.001
  High 09.50 23.81%  
  1. MST Median Survival Time, PS Performance Status, CRP C-Reactive Protein, HP Helicobacter Pylori, CEA Carcinoembryonic Antigen, CA 19–9 Cancer Antigen 19–9, CA 72–4 Cancer Antigen 72–4.